Clene Inc. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Clene Inc. priced a registered direct offering of 1,219,513 shares at $3.28 per share for gross proceeds of $4.0 million, closing September 17, 2026. Purchasers include Chairman David Matlin, founding investor Kensington Capital Holdings, CEO Robert Etherington, and other existing shareholders—no placement agent or underwriter involved. Net proceeds fund operations through mid-Q1 2027, primarily for CNM-Au8 regulatory preparation, expanded access protocols, and manufacturing expansion.
Why this rating
At ~$40.4M market cap, $4M capital raise is ~10% of company value—meaningful for runway but not transformational. Insider participation (Chairman, CEO) is positive signal; however, clinical-stage biotech burns cash rapidly. Dilution is material (~3% on 1.22M shares issued) but survivable. Event extends runway 8–9 months only—significant financing pressure remains.
Price action (we called it neutral)
before filing · preread $3.86 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.